October 09, 2019 SITC 2019 preview – Nextcure’s time to shine The biotech calendar’s next key conference gets under way in a month, and a presentation by Nextcure will be a focus for some investors.
September 13, 2018 Another must-have oncolytic virus asset for big pharma Boehringer Ingelheim struck a deal with the oncolytic virus company Viratherapeutics in 2016, and it has clearly seen something extraordinary in the intervening two years.
